Sartorius AG Preference Shares
EURO STOXX 600Last update: May 9, 2026 at 09:32
Dividend Safety Rating
SRT3.DE's dividend appears safe and well-supported. Strengths include a 31.5% earnings payout ratio & 11.9% fcf payout ratio. Areas of concern: 2.9x interest coverage & 0.9x current ratio. The dividend has been growing at a 15.50% 5-year CAGR.
Based on 15 of 15 metrics
Strengths
- Earnings Payout Ratio: 31.5%Low earnings payout ratio leaves room to grow the dividend.
- FCF Payout Ratio: 11.9%Free cash flow comfortably covers the dividend.
- CFO Payout Ratio: 9.4%Operating cash flow strongly supports the payout.
Risks
- Interest Coverage: 2.9xInterest coverage is thin relative to debt servicing.
- Current Ratio: 0.9xLimited short-term liquidity to meet obligations.
- Return on Equity: 6.2%Return on equity is below industry norms.
Payout & Coverage
SafeBalance Sheet
CautionProfitability
CautionDividend Track Record
Very SafeAbout Sartorius AG Preference Shares
Sartorius AG Preference Shares represent a class of non-voting equity in Sartorius AG, a leading supplier of laboratory and bioprocess solutions for the life sciences and biopharmaceutical industries. These shares primarily grant holders preferential dividend rights, often at higher rates than ordinary shares, appealing to investors prioritizing income stability over corporate governance influence. Sartorius AG, headquartered in Göttingen, Germany, and founded in 1870, develops innovative instruments like pipettes, balances, and water purification systems, alongside bioprocess technologies for drug discovery, development, and manufacturing of biologics, vaccines, and therapies. The company operates through Bioprocess Solutions and Lab Products & Services divisions, serving pharmaceutical, biotechnology, research institutes, and industries such as oncology, immunology, and cell therapy globally with around 13,685 employees. With 34,813,621 preference shares outstanding (excluding treasury shares), these instruments underscore Sartorius AG's pivotal role in advancing biopharmaceutical innovation and supporting scalable production processes amid growing demand for advanced therapies.
Dividend Overview
Dividend Yield
0.34%
Annual Dividend
€0.74
Frequency
Annual
Payout Ratio
31.49%
FCF Payout Ratio
11.89%
Stock Price
€216.90
52-Week Range
€175.95 – €267.70
Dividend History (2016–2025)
SRT3.DE annual dividend per share and yield history
Earnings & Profitability
SRT3.DE earnings per share and net profit margin
Key Dates
Last Ex-Dividend Date
March 27, 2026
Next Payment Date
—
Dividend Growth
3-Year Dividend CAGR
-16.26%
5-Year Dividend CAGR
15.50%
10-Year Dividend CAGR
27.06%
3-Year Total Growth
-41.27%
5-Year Total Growth
105.56%
10-Year Total Growth
996.30%
Income Calculator
Similar Dividend Stocks
Frequently Asked Questions
What is SRT3.DE's current dividend yield?
When is SRT3.DE's next dividend payment date?
How much does SRT3.DE pay in dividends per year?
Has SRT3.DE been increasing its dividend?
Is SRT3.DE's dividend safe?
How is SRT3.DE's Dividend Safety Rating calculated?
Want to understand how we rate dividend safety? Read our full methodology
Track SRT3.DE Dividends with OnlyDividends
What will SRT3.DE actually pay you after taxes? Track every payout, get notified on payment dates, and stop guessing.
This page is not investment advice. The content is for informational purposes only and should not be construed as a recommendation to buy, sell, or hold any security. Always do your own research and consult a qualified financial advisor before making investment decisions.
Financial data, including dividend history, earnings, balance sheet metrics, and the Dividend Safety Rating, is provided for informational purposes only. Data may be delayed or differ from official filings. Past performance does not guarantee future results. Always verify with official sources before making investment decisions.
Market data provided by Twelve Data.